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Summary In this paper an overview is presented on what is currently known of fatigue in cancer. Fatigue is considered to be a multi-dimensional concept, that should be measured as such. However, fatigue has been assessed mostly by single items in general symptom checklists. The few specific instruments that have been used in cancer patient populations are discussed. The majority of cancer patients, about 70%, report feelings of fatigue during radio-or chemotherapy. Follow-up results show that, at least for some diagnoses, patients remain fatigued long after treatment has ended. Somatic and psychological mechanisms that have been proposed to explain fatigue are discussed. It is argued that the significance of the results obtained on fatigue as a sympton in cancer depends on comparison with other patient and non-patient populations. Also the occurrence of a response-shift has to be considered, leading to under reporting of fatigue. Finally, possible interventions to decrease feelings of fatigue are presented.
Cancer and its treatment are characterised by a variety of possible symptoms such as pain, decreased appetite, ulcers in the mouth, hair-loss, nausea and vomiting, shortness of breath, fatigue and a general deterioration of physical condition. Of all these symptoms, fatigue is without doubt the symptom most commonly experienced. It can be the first manifestation of an underlying disease process. Subsequent treatment with surgery, radio-or chemotherapy may induce or worsen feelings of fatigue. The final stages of the disease process are often characterised by exhaustion and a complete loss of energy. The consequences of fatigue are reflected in its detrimental effects on patients quality of life (Achard & Zitoun, 1991) , self-care activities (Rhodes et al., 1988) and social activities (Cristensen, 1989) .
To date there are few studies which systematically register how many cancer patients experience fatigue, in which stage of the disease process and to what extent. To give an indication, a literature-search using MEDLINE with CD-ROM over the period 1980 to 1991 yielded nine references in which 'fatigue' was included in the title and 'cancer' was included in title, keyword or abstract. Eight of these references pertained to nursing research.
An appraisal of the research literature concerning fatigue in cancer is presented in this paper to give an overview of what is currently known. Literature, other than obtained using the MEDLINE-procedure, was gathered either by searching for studies in which fatigue was assessed as part of patient functioning or through references of the papers obtained. This procedure does evidently not lead to an exhaustive list of all the studies which included fatigue as an outcome-variable. However, we think to have obtained a representative sample. Topics that will be discussed are: the conceptualisation of fatigue and its measurement, prevalence rates of fatigue during and after treatment and somatic and psychological correlates of fatigue. Finally, considerations with regard to research and interventions will be discussed. Without specification of its exact meaning, fatigue is reported as a symptom of many other diseases including multiple sclerosis and systemic lupus erythematosus, myocardial infarction, renal disease, the Chronic Fatigue Syndrome and lung-emphysema (Appels & Mulder, 1988; Krupp et al., 1989; Srivastava, 1989) . Fatigue is also universally considered to be a symptom of depression.
In addition to a symptom of a somatic or psychological condition, fatigue might also be conceived as a mood-state. Moods in general have been described as states of action readiness or action preparedness. Consequently, fatigue has been described as a mood-state characterised by de-activation or low-action-preparedness (Frijda, 1986) .
The reduced performance resulting from long or intense cognitive or physical functioning, which may suggest a simple cause effect relationship, has traditionally been equivalent to fatigue in occupational psychology. However, reports of fatigue appear to depend heavily on being motivated to adequate performance. Therefore, fatigue has more recently been described as a lack of motivation to perform (Meyman, 1991) .
Finally, fatigue has been thought of as either an acute or a chronic phenomenon. Not only are there differences in causative and maintaining factors for the acute or chronic fatigue, but the description of these experiences may also differ.
The foregoing implicates that fatigue is a multidimensional concept with several modes of expression: physical, cognitive, in activity or in motivation, acute or chronic. Which of these aspects describes the fatigue experience of cancer patients best is currently unknown.
been measured most of the time by single items in general symptom checklists such as the Symptom Distress Scale (McCorkle & Quint, 1983; Oberst et al., 1991) , the Symptom Profile (King et al., 1985) , the Rotterdam Symptom Checklist (de Haes et al., 1990) or by the 'fatigue' subscale of the Profile of Mood States (POMS) (Spiegel et al., 1981) .
More specific instruments have been used to assess fatigue in cancer patient populations. These can be divided in onedimensional or multidimensional instruments. The simplest one-dimensional measure of tiredness is the Rhoten Fatigue Scale (RFS), in which a visual analogue scale is combined with a numerical ten points rating scale, ranging from 'not tired, full of energy' to 'total exhaustion' (Rhoten, 1982; Blesch et al., 1991) . Pearson and Byars (1956) developed a ten item Fatigue Feeling Checklist (PBFFC), that was used in studies on the effects of radiotherapy (Haylock & Hart, 1979) and chemotherapy (Cristensen, 1989) . This instrument contains ten adjectives, ranging from 'extremely peppy' to 'extremely tired'. Estimates of reliability and validity are lacking (Piper, 1988) .
The Fatigue Symptom Checklist (FSCL) is a multidimensional questionnaire, aiming to assess fatigue in a work situation (Kogi et al., 1970) . It was used by Haylock and Hart (1979) and by Kobashi and co-workers (Kobashi et al., 1985) in a study on radiotherapy patients. The Piper and colleagues set out to develop an instrument to measure the experience of fatigue of patients, the Piper Fatigue Self-report Scale (PFS) (Piper et al., 1989 (King et al., 1985) . The Andersen & Tewfik, 1985; Oberst et al., 1991) . Chemotherapy also results in a high incidence of fatigue. Prevalence rates between 75% and 100% of tiredness during chemotherapy have been reported (Linssen et al., 1979; Nerenz et al., 1982; Cassileth et al., 1985; de Haes et al., 1987; Nail & King, 1987; Love et al., 1989) . Finally, feelings of tiredness are characteristic for the period of convalescence after surgery (Christensen et al., 1982) .
Follow-up results show that, at least for some diagnoses, many patients remain fatigued after treatment has ended. Devlen et al. (1987) examined 120 newly diagnosed patients with Hodgkin's or non-Hodgkin's disease in a prospective study. Although most patients were no longer receiving treatment and were free of disease at a one year follow-up, 42% of these patients continued to complain of loss of energy and 32% of tiredness. In a survey among members of the patientorganisation of Hodgkin and non-Hodgkin patients (Breij & Visser, 1990) , 61% of the subjects reported fatigue that was described as 'moderate to quite bad'. Treatment had ended more than 2 years prior to the survey in 60% of the sample. Berglund et al. (1991) assessed late effects of adjuvant treatment on perceived health of breast cancer patients, free from recurrence 2 to 10 years after primary therapy. Patients who had received radiotherapy reported decreased stamina (75%) more frequently than did chemotherapy patients (61%). Finally, the psychological problems that develop in long term survivors of Hodgkin's disease were examined in a crosssectional survey of 403 patients (Fobair et al., 1986) . The median time since treatment was 9 years. Results indicated that energy had not returned to patients' satisfaction in 37% of the cases.
In the foregoing studies, single items were used to assess fatigue. Instruments specifically developed to measure fatigue were used in the studies discussed next. Three studies have assessed the fatigue experience of patients receiving radiotherapy. Haylock and Hart (1979) (Yasko & Greene, 1987; Bruera & MacDonald, 1988) .
Also, anaemia is frequently mentioned as a possible factor in fatigue. However, a correlation between fatigue and the degree of anaemia is rarely found (Piper et al., 1987) . Anaemia is probably only a factor with regard to fatigue when haemoglobin levels are extremely low (Bruera & MacDonald, 1988) .
Day-time tiredness can be induced by drugs with a sedative (main or side) effect, including anti-emetics, analgesics or sleeping-agents (Aistars, 1987) . Tiredness can also result from insomnia, which is a common problem of cancer patients (McCorkle & Quint, 1983; Cannici et al., 1983; Kaye et al., 1983; Silberfarb et al., 1985) . Among other things, difficulty getting to sleep and difficulty staying asleep might result from pain. A significant correlation (r = .48 P <.0001) has been found between the severity of pain and the intensity of fatigue (Blesch et al., 1991) . Finally, it was made plausible that Immobilisation was an important factor for a postoperative increase in heart rate during exercise which was significantly related to an increase in reports of fatigue (Christensen et al., 1982; Zeiderman et al., 1990 (Hayes, 1991) . (Piper, 1990) . Women receiving treatment for breast cancer were asked what they believed contributed most directly to or caused their fatigue. Their answers indicated that changes in psychological patterns such as increased stress, worry, depression and anxiety contributed to fatigue most. Fatigue was found to be significantly related to mood (Cristensen, 1989; Blesch et al., 1991) . Nerenz et al. (1982) found tiredness to be strongly associated with the emotional distress experienced during chemotherapy treatment. Finally, patients whose energy level had not returned to normal after treatment for Hodgkin's disease, were also more likely to have elevated depression scores (Fobair et al., 1986) .
Research issues
From the foregoing it can be concluded that research in the domain of fatigue in cancer is only in its infancy. Further research has to address issues such as (a) prevalence rate of fatigue at different stages of the disease, including follow-up data after successful treatment (b) the somatic, behavioral and psychological correlates of fatigue and (c) the consequences of this particular symptom for the well-being of the patient.
An important omission in most research on cancer fatigue is the lack of comparison-groups (Irvine et al., 1991) . To be able to determine the significance of the results obtained, the prevalence and intensity of fatigue in cancer patients need to be compared with the prevalence and intensity of fatigue in patients with other diseases or with non-patient populations. Prevalence rates between 14 and 34% of tiredness have been found in community surveys (Chen, 1986; Rillsdale, 1991) . This means that the prevalence rates of fatigue in cancer patients should be rather high, to justify the conclusion that patients differ in their fatigue experience from the general population. Pickard et al. (1991) did compare the fatigue scores of women receiving chemotherapy for ovarian cancer, with the scores a convenience sample of apparently healthy adult women. The difference between the mean fatigue scores of both groups did not reach significance. This lack of difference may be explained satisfactorily by the small samples used in this study. However, there is another possible explanation for the similarity in fatigue scores of patients and non-patients. When comparing the fatigue scores of cancer patients with those of other populations, or when comparing fatigue scores obtained before treatment with those obtained after treatment, an interpretation problem arises; the problem of a (response shift' having occurred in the sample of cancer patients. The term 'response shift' refers to the change in a person's internal standard for determining his or her level of functioning on a given dimension (Breetvelt & van Dam, 1991) . This shift in standard may result from a training course, an intervention or a major life-event. The experience of fatigue during radio-or chemotherapy, could change a patient's standard of measurement concerning fatigue. What has been perceived to be 'intense' fatigue before treatment, might be labelled 'slightly' fatigued after having experienced exhaustion during treatment. The possible occurrence of a 'response shift' complicates the interpretation of comparison data. These interpretation problems have been described in studies evaluating the effectiveness of training or therapy interventions. In this field of study methods have been recommended to ascertain whether a 'response shift' has occurred. Howard et al. (Breetvelt & Van Dam, 1991) advocated the use of 'then'-ratings, on which subjects indicated, in retrospect after the treatment, how they rated their functioning before treatment. As the 'then' pre-treatment scores were assessed at the same time as the posttreatment scores, it is probable that these scores were assigned from the same perspective and therefore are free from 'response shift' bias. Further research has to indicate the applicability of techniques for the assessment of a 'response shift' with regard to symptom reporting.
Concluding remarks
The hope is that good measurement and a better understanding of the course and correlates of fatigue may result in recommendations for interventions. These recommendations would then require systematic testing in populations of cancer patients. At this moment we can only speculate about possible beneficial interventions. Results have indicated that patients do no always expect fatigue to be a side-effect of treatment (Cassileth et al., 1985; Love et al., 1989; Tierney et al., 1991) . Preparatory information on what to expect in terms of fatigue during and after treatment, could enhance the ability of patients to cope with this symptom. Good information may also prevent unnecessary worries about fatigue indicating tumour growth or treatment failure.
In healthy individuals it is generally assumed that exercise is effective in reducing fatigue. So far, this assumption has been tested with cancer patients in preliminary studies only (Questad, 1983; McVicar & Winningham, 1984; Young & Sexton, 1991) . Due to limitations of these studies no firm conclusions can be drawn. However, the results obtained are promising enough to stimulate further research.
The expectation as to the effect of physical exercise has been attributed a role in the maintenance of fatigue (Wessely et al., 1990) . Anticipating fatigue with certain activities, will lead to avoidance. Such an anticipation may be based on one or a few negative experiences, for instance after a too enthusiastic start of activities in the early phase of convalescence. Avoidance makes the person unfit, leading to easy development of fatigue when physical exercise is again undertaken.
Finally, studies evaluating the effectiveness of a psychotherapeutic intervention for cancer patients have found decreased fatigue-scores as a result of these interventions (Spiegel et al., 1981; Forester et al., 1985; Fawzy et al., 1990) . Therefore interventions aimed at reducing emotional distress or enhance coping responses may also be an effective way to decrease feelings of fatigue.
Further research might give information on those factors that differentiate between patients for whom the fatigue is in part the result of psychological or behavioral factors, from those patients whose fatigue is mainly somatic in origin. Being able to differentiate means that the interventions offered can be more customised to the needs of the individual patient.
At this moment no other conclusion remains then that our knowledge of fatigue as experienced by cancer patients is limited. Much research will be needed to clarify the undoubtedly complex somatic and psychological mechanisms responsible for the development, maintenance and treatment of fatigue.
